- Shares of immune biopharma NexImmune have cratered 90% from their IPO pricing as early returns from two Phase 1/2 trials have failed to impress.
- In theory, the output from its AIM platform should improve upon CAR T therapies, as they are more specific and thus should be more effective and less toxic.
- Trading at a discount to cash, but with only enough to get NexImmune to 2Q23 (covering two data updates in 2H22), the recent purchases by three insiders merited further investigation.
- A full investment analysis follows in the paragraphs below.
For further details see:
NexImmune: Selling For Under Cash Value